| Document |
Document Title |
|
WO/2023/275333A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2023/274390A1 |
Disclosed are a Bruton's tyrosine kinase and a mutant degrader thereof, or a stereoisomer thereof, or a stereoisomer mixture thereof or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug f...
|
|
WO/2023/275336A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/272720A1 |
PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor comp...
|
|
WO/2023/279105A1 |
Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided ...
|
|
WO/2023/277015A1 |
The present invention provides a compound having outstanding effectiveness against resistant harmful arthropods, a composition containing the same, and a control method. A compound represented by formula (I) [in which R1 denotes a C1-C6 ...
|
|
WO/2022/271901A1 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, A, R2, R4, R5, L and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds...
|
|
WO/2022/269251A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA, RB, RC and RD are as defined herein.
|
|
WO/2022/268230A1 |
The present invention provides a compound as a KIF18A inhibitor. Specifically, the present invention provides a compound having a structure as represented by the following formula (I), or an optical isomer, pharmaceutically acceptable sa...
|
|
WO/2022/266711A1 |
This disclosure relates to compounds of formula (I), which are modulators of STING. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of using compounds of formula (I) in the treatment or prev...
|
|
WO/2022/271612A1 |
The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/270487A1 |
The present invention addresses the problem of providing a compound having an ETA receptor antagonistic activity and others. The problem can be solved by a compound represented by formula (1) [wherein variables are as defined in the desc...
|
|
WO/2022/267673A1 |
The present invention relates to the technical field of biomedicines, and in particular to a sulfoximide substituted indazole compound, or an isomer and pharmaceutically acceptable salt thereof. The structure of the compound is shown as ...
|
|
WO/2022/271961A1 |
An oral feline feed and a method of controlling ticks in a feline in need thereof by orally administering to the feline a daily feed comprising an effective amount of a isoxazoline for an effective time to thereby cause the amount of iso...
|
|
WO/2022/271677A1 |
The application relates to diacylglycerol kinase modulating quinazolin-2-one derivatives of the general Formula (I), and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV ...
|
|
WO/2022/269508A1 |
The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compo...
|
|
WO/2022/268154A1 |
Provided are a class of compounds for the treatment and prevention of hepatitis B virus infection, and an isomer or a pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound, a ...
|
|
WO/2022/272060A1 |
Described herein are compounds that are EP2 antagonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditi...
|
|
WO/2022/270987A1 |
The present invention relates to a novel compound that induces selective degradation of AURKA, and specifically provides a bifunctional compound in which an AURKA binding moiety and an E3 ubiquitin ligase binding moiety are linked by a c...
|
|
WO/2022/271749A1 |
The present disclosure provides a compound represented by structural formula (I):or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/268025A1 |
Provided are a new class of compounds having an ATR inhibitory effect and as represented by formula I, and the use thereof in the preparation of a drug.
|
|
WO/2022/270628A1 |
The present invention provides a compound that is useful for treatment or prevention of RS virus infection. The present invention pertains to: a compound represented by formula (I): (where Y1, Y2, Y3, X4, etc., are as defined in the sp...
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/263573A1 |
The present invention provides compounds of formula (I) which are useful for long-lasting treatment and control of pests, for example fleas and ticks, in companion animals and livestock, and pharmaceutical compositions and methods of usi...
|
|
WO/2022/266363A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibit...
|
|
WO/2022/262782A1 |
Disclosed are a series of glutarimide-substituted isoxazole compounds and an application thereof, and specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/263676A1 |
The invention concerns a compound of formula (I), a pharmaceutical formulation comprising the compound of formula (I) and use of the pharmaceutical composition for treating fibrotic, inflammatory, diabetic or cognitive disease.
|
|
WO/2022/263530A1 |
The present invention provides compounds of formula (I): Formula (I) which are useful for long-lasting treatment and control of pests, for example fleas and ticks, in companion animals and livestock, and pharmaceutical compositions and m...
|
|
WO/2022/265993A1 |
This disclosure provides compounds of Formula (I), Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Ka). These chemical entities are useful,...
|
|
WO/2022/266236A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2022/261643A1 |
The present disclosure relates to methods of treating cancers, including metastasized cancers by administering a potent CDK 2/4/6 inhibitor of the formula (I), or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
|
|
WO/2022/259985A1 |
A compound represented by formula (1) or a salt thereof, or an N-oxide thereof. In the formula: A is a structure represented by A-1 or A-0; D is a structure represented by D-1 or D-2; and B is a structure represented by B-1, B-2, B-3, B-...
|
|
WO/2022/261473A1 |
The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory sy...
|
|
WO/2022/260096A1 |
Provided is a photoelectric conversion element material that is for an imaging element and that contributes to production of a photoelectric conversion element that is for an imaging element and that exhibits excellent dark current and e...
|
|
WO/2022/259859A1 |
The present invention provides an organic light-emitting element having a first electrode, a second electrode, and an organic compound layer disposed between the first and second electrodes, wherein the organic light-emitting element is ...
|
|
WO/2022/261296A1 |
Small molecule compounds that selectively bind to non-canonical G-quadruplex (G4) structures, such as G4s in DNA found in various types of genes described herein, along with methods of using the compounds to reduce or inhibit protein (e....
|
|
WO/2022/256284A1 |
Disclosed are compounds of Formula (I), including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, A and T are as defined in the disclosure. Also disclosed are compositions containing the compounds of For...
|
|
WO/2022/253362A1 |
The present invention belongs to the field of agricultural herbicides, and particularly relates to an aryl isoxazoline compound and a use thereof. The aryl isoxazoline compound is represented by general formula (I). The compound of gener...
|
|
WO/2022/026565A9 |
Provided and set forth herein are certain cyclized acetamido derivatives that are DNA Polymerase Theta (Ροlθ) inhibitors of Formula (I) and Formula (II). Also, provided are pharmaceutical compositions comprising such compounds, and me...
|
|
WO/2022/256702A1 |
Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and m...
|
|
WO/2022/255463A1 |
The present invention addresses the problem of providing a canine heartworm disease control agent for animals, said agent exhibiting an excellent effect when administered to a target animal, and a method for using a canine heartworm dise...
|
|
WO/2022/255764A1 |
The present invention relates to a novel oxazole derivative, a preparation method therefor, and a pharmaceutical composition containing same as an active ingredient for preventing or treating an allergic disease such as asthma or atopy. ...
|
|
WO/2022/253959A1 |
The present invention relates to compounds, pharmaceutical compositions and medicaments suitable for use in the prevention and/or treatment of neurodegenerative disorders, such as for example demyelinating diseases. These compounds have ...
|
|
WO/2022/253333A1 |
A class of amide compounds and an application thereof. Specifically disclosed are compounds represented by formula (P) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/256676A1 |
Compounds of formula I, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and ...
|
|
WO/2022/254388A1 |
The present invention discloses novel SARS-CoV-2 inhibitors for therapeutic formulations and methods for treating SARS-CoV-2 infections. The compounds exhibit unique pharmacophoric features including conformational flexibility and spatia...
|
|
WO/2022/253328A1 |
An HPK1 kinase inhibitor, and a preparation method therefor and an application thereof. Specifically, a compound shown in formula (I), the compound having HPK1 inhibitory activity and being used for preparing a pharmaceutical composition...
|
|
WO/2022/253252A1 |
Disclosed herein are compounds of Formula (I) : or pharmaceutically acceptable salts thereof. Also disclosed are methods of using such compounds to modulate or inhibit the enzymatic activity of hematopoietic progenitor kinase (HPK1), and...
|
|
WO/2022/253261A1 |
The present application relates to the field of medicinal chemistry. The present application relates to a hydrate crystal form of lazertinib monomethanesulfonate, a preparation method therefor and an application thereof. The hydrate crys...
|
